BioWorld Science: The Daily Drug R&D News Source

Brain path could relieve pain as an alternative to opioids without producing dependence
Scientists at the University of Chicago have discovered a signaling pathway guided by nicotinic acetylcholine receptors (nAChRs) that could relieve pain even when tolerance to opioids was present. This mechanism did not produce dependence after treatment and could be explored to develop new drugs.

New Celexor Bio to focus on cell depletion of pathologic cells in autoimmune and inflammatory disorders
Epitope editing in hematopoietic cells provides CAR T immunotherapy against all types of blood cancer
Replay’s Syena and Jura Bio collaborate to advance TCR-NK therapies for cancer
Seinda Pharmaceutical patents new peptides for ocular conditions

Brain path could relieve pain as an alternative to opioids without producing dependence
Scientists at the University of Chicago have discovered a signaling pathway guided by nicotinic acetylcholine receptors (nAChRs) that could relieve pain even when tolerance to opioids was present. This mechanism did not produce dependence after treatment and could be explored to develop new drugs.
New Celexor Bio to focus on cell depletion of pathologic cells in autoimmune and inflammatory disorders
Inmagene Biopharmaceuticals Technology (Shanghai) Co. Ltd. and biotech investment firm Aditum Bio Management Company LLC have announced the formation of Celexor Bio, a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders. Celexor has been formed based on Inmagene’s IMG-018, a plasmacytoid dendritic cell (pDC)-depleting antibody targeting immunoglobulin-like transcript 7 (ILT7).
Epitope editing in hematopoietic cells provides CAR T immunotherapy against all types of blood cancer
A new method of CAR T-cell immunotherapy developed by researchers at the University of Pennsylvania Perelman School of Medicine could serve as a treatment for most blood cancers. Until now, CAR T-based immunotherapy for hematological malignancies has targeted the antigens CD19 for B cells, CD7 for T cells, BCMA for myeloma, and CD33 for AML.
Replay’s Syena and Jura Bio collaborate to advance TCR-NK therapies for cancer
Replay Holdings LLC has announced a research collaboration between Jura Bio Inc. and Syena, a cell therapy product company launched by Replay and the University of Texas MD Anderson Cancer Center earlier this year, to develop T-cell receptor (TCR)-based therapies.
Seinda Pharmaceutical patents new peptides for ocular conditions
Seinda Pharmaceutical Corp. has disclosed peptides reported to be useful for the treatment of corneal epithelial defect, corneal neovascularization and dry eye.
Holiday notice
In accordance with the publishing schedule, BioWorld Science will not be published on Monday, Sept. 25, 2023.
Other news to note for Sept. 22, 2023
Additional early-stage research and drug discovery news in brief.
Via Nova Therapeutics receives FDA clearance of IND for influenza A nucleoprotein inhibitor
Via Nova Therapeutics Inc. has received clearance of its IND application from the FDA for its influenza A nucleoprotein inhibitor, VNT-101. The novel investigational small molecule is directed against a novel target, the influenza A nucleoprotein, and is being developed for treatment of seasonal influenza A infection.
Honokiol derivative shows potent activity in models of human nasopharyngeal carcinoma
Researchers from Bengbu Medical College have discovered new derivatives of honokiol, a biphenyl neolignan extracted from Magnolia species, which has been shown to possess pharmacological properties, including anticancer, anti-inflammatory, antioxidant, anti-infectious and neuroprotective activities. A total of 21 new honokiol derivatives were synthesized, with derivative [I] being selected as the lead with the most potent in vitro cytotoxic activity.

Today's news in brief

BioWorld

BioWorld MedTech

BioWorld Asia

BioWorld Science

BioWorld Premium